Financings Of The Fortnight: Haircuts And Postponements Increasing As IPO Burst Slows Down
This article was originally published in The Pink Sheet Daily
Executive Summary
The IPO boom of 2013 is showing signs of slowing, while class of 2012 companies are seeing stock prices decline. Plus news on recent financings by Relypsa, Synta Pharmaceuticals, ArGEN-X and Karyopharm Therapeutics.
You may also be interested in...
Biopharma Dealmaking Quarterly Statistics, Q4 2013
Biopharma financing totaled $6.4 billion, a 39% increase over Q3. Twenty-three M&As were completed with a combined potential value of $19.8 billion, and there were 103 biopharma alliances totaling $2.5 billion in potential pre-commercialization value, down 25% from the previous quarter.
Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Analysts Remain Skeptical
Synta provided one-year follow up data for its Phase IIb/III trial testing ganetespib in NSCLC, and revealed some protocol changes which it believes will de-risk the Phase III design. Analysts on the third quarter earnings call by and large bought into the story, but some skepticism remains.
OrbiMed’s Big Fund Signals A Potential Return To Health For VCs
The largest dedicated health care investor has closed a huge new fund, which came almost entirely from existing investors. OrbiMed isn’t the only firm capitalizing on the robust biotech IPO market. A few VCs are starting to take gains from IPO winners through secondary offerings.